CANC is an exchange-traded fund — it holds a basket of underlying assets rather than being a single operating company.
Company fundamentals like P/E, revenue, EPS and profit margins don't apply to a fund — its value comes from the assets it holds, not its own earnings. Use the price chart, options and model forecast below for fund-level analysis.
An institutional-grade, numbers-driven thesis on CANC — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 18, 2026, TradersQuant's model rates Tema Oncology ETF (CANC) 55/100 with a 12-month base-case forecast of $54.12 — +25.0% versus the current price of $43.28. Tema Oncology ETF trades at $43.28 in the Financial Services sector, with a market capitalisation of $137.3M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for CANC is $54.12, implying +25.0% versus the current price. The model's 12-month scenario range runs from $49.88 (bear) to $60.73 (bull), with a base case of $54.12.
CANC currently carries a TradersQuant composite score of 55/100, which we read as a neutral-to-watch signal. Our 12-month price target of $54.12 implies +25.0% from $43.28. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for CANC is $54.12, about +25.0% versus the latest price of $43.28.
TradersQuant's 12-month model forecast for CANC is a base case of $54.12, ranging from $49.88 (bear) to $60.73 (bull), an expected return of +25.0%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for CANC over the next 12 months is $54.12 in the base case (bear $49.88, bull $60.73), versus today's price of $43.28. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for CANC — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates CANC's fair value at $55.15, implying +27.4% of expected upside versus the current price.
Tema Oncology ETF does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
